We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany, the U.S. indexes were all green on Monday. The headlines were dominated by news regarding self-driving car projects from two separate tech giants, as well as the FDA approval of Clovis Oncology’s new ovarian cancer drug.
Google parent Alphabet Inc. (GOOGL - Free Report) formally announced that Waymo, its new self-driving car unit—previously known as the Google Self-Driving Car Project—and Fiat Chrysler Automobiles have completed their highly-anticipated production self-driving test vehicles.
Shares of BlackBerry gained nearly 3% in early morning trading Monday, just a day before the company is set to report its third-quarter earnings. With two other stories involving BlackBerry breaking this week—including the news that it is entering the self-driving car business—many investors are getting excited about this stock right now.
Shares of Clovis Oncology soared over 15% in morning trading Monday after the pharmaceutical company received approval for its new PARP inhibitor, “Rubraca,” which treats advanced ovarian cancer in women.
Stocks that Aren't in the News. Yet.
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of +26% per year. See these high-potential stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stock Market Roundup, Dec. 19: GOOGL & BBRY Self-Driving Cars, CLVS Soars
While there was some afternoon volatility in international markets due to a pair of tragedies in Turkey and Germany, the U.S. indexes were all green on Monday. The headlines were dominated by news regarding self-driving car projects from two separate tech giants, as well as the FDA approval of Clovis Oncology’s new ovarian cancer drug.
Zacks Rank #1 (Strong Buy) Biggest Movers
Value: Angang Steel - + 11.44%
Growth: USD Partners (USDP - Free Report) - +7.99%
Momentum: Mannkind Corp. (MNKD - Free Report) - +27.32%
VGM: Azure Midstream - +9.01%
Income: USDP
Major Indexes
DOW: 19,881.25 / +37.84 / +0.19%
S&P 500: 5,451.16/ +14.00 / +0.26%
NASDAQ: 2,261.36 /+3.29 / +0.15%
Top Headlines
Google's Waymo Completes Self-Driving Pacifica Minivan Test
Google parent Alphabet Inc. (GOOGL - Free Report) formally announced that Waymo, its new self-driving car unit—previously known as the Google Self-Driving Car Project—and Fiat Chrysler Automobiles have completed their highly-anticipated production self-driving test vehicles.
Here's Why BlackBerry Stock Is Gaining Ahead Of Earnings
Shares of BlackBerry gained nearly 3% in early morning trading Monday, just a day before the company is set to report its third-quarter earnings. With two other stories involving BlackBerry breaking this week—including the news that it is entering the self-driving car business—many investors are getting excited about this stock right now.
Here's Why Clovis Oncology Stock Is Soaring Today
Shares of Clovis Oncology soared over 15% in morning trading Monday after the pharmaceutical company received approval for its new PARP inhibitor, “Rubraca,” which treats advanced ovarian cancer in women.
Stocks that Aren't in the News. Yet.
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of +26% per year. See these high-potential stocks free >>